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Abstract 
The use of gene therapy (GT) for the treatment of primary immune deficiencies (PID) including severe combined 
immune deficiency (SCID) has progressed significantly in the recent years. In particular, long-term studies have shown 
that adenosine deaminase (ADA) gene delivery into ADA-deficient hematopoietic stem cells that are then trans-
planted into the patients corrects the abnormal function of the ADA enzyme, which leads to immune reconstitution. 
In contrast, the outcome was disappointing for patients with X-linked SCID, Wiskott–Aldrich syndrome and chronic 
granulomatous disease who received GT followed by autologous gene corrected transplantations, as many devel-
oped hematological malignancies. The malignancies were attributed to the predilection of the viruses used for gene 
delivery to integrated at oncogenic areas. The availability of safer and more efficient self-inactivating lentiviruses for 
gene delivery has reignited the interest in GT for many PID that are now in various stages of pre-clinical studies and 
clinical trials. Moreover, advances in early diagnosis of PID and gene editing technology coupled with enhanced abili-
ties to generate and manipulate stem cells ex vivo are expected to further contribute to the benefit of GT for PID. Here 
we review the past, the present and the future of GT for PID, with particular emphasis on the Canadian perspective.
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Background
Primary immune deficiencies (PID) are a group of inher-
ited immune disorders that can result in predisposition 
to infections, immune dysregulation, autoimmunity or 
malignancy. The introduction of newborn screening 
for severe immune defects as well as better diagnostic 
modalities and awareness have contributed to increase 
in identification of PID [1]. Early diagnosis, antibiotic 
prophylaxis and treatment, immunoglobulin replacement 
and immunosuppressive medications can help prevent 
or ameliorate many of the PID manifestations. However, 
such treatments often require life-long administration 
and are associated with significant emotional and finan-
cial burden to patients, families and society. Moreo-
ver, such treatments may lose their effectiveness over 
time and often do not prevent immune dysregulation 
disorders or malignancy. Hence, the ultimate cure for 
most PID requires correction of the defective gene 
responsible for the immune deficiency.
Hematopoietic stem cell transplantations for primary 
immune deficiency
Hematopoietic stem cell transplantations (HSCT) involve 
the infusion of stem cells typically obtained from bone 
marrow, peripheral blood or umbilical cord blood to re-
establish the hematopoietic and/or immune function. 
Since the original description of allogeneic bone marrow 
transplantations for patients suffering from PID in 1968, 
HSCT have been performed across the world for many 
severe immune defects [2, 3]. These conditions range from 
severe combined immunodeficiency (SCID) encompass-
ing all lymphoid lineages such as adenosine deaminase 
(ADA) deficiency, lymphoid subtypes such as “common” 
gamma chain (γc) defects to specific T cell defects such 
as immune dysregulation, polyendocrinopathy, enteropa-
thy, X-linked (IPEX) syndrome. Other PID that can be 
treated by HSCT include myeloid abnormalities such as 
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Wiskott–Aldrich syndrome (WAS), leukocyte adhesion 
defect (LAD) or chronic granulomatous diseases (CGD). 
Throughout the years, HSCT using allogenic human leu-
kocyte antigens (HLA) matched or mis-matched donors 
have cured thousands of patients with PID. However, allo-
geneic HSCT are associated with many complications. 
Chemotherapy is often required prior to HSCT to elimi-
nate the recipient’s residual immune system, which helps 
prevent rejection of the donor cells. Moreover, many 
patients experience significant graft versus host (GvH) 
disease where the donor’s competent immune system 
recognizes the recipient HLA-expressing cells as foreign 
and attacks the recipient organs. When HLA-matched or 
mismatched unrelated donors are used for transplanting 
patients with PID, which occurs in the majority of HSCT, 
the risk for GvH disease increases to more than 70% [4]. 
Although earlier diagnosis, improved infections con-
trol, better HLA matching and lesser toxic conditioning 
regimens are expected to further improve the outcomes 
of HSCT, such procedures continue to carry significant 
complications.
Gene therapy
Gene therapy (GT), i.e. the use of genetic material 
to modify cells, has been investigated for numerous 
conditions since the development of recombinant DNA 
technology in the late 1970’s. Different forms of GT are 
being explored, including gene insertion into cells ex vivo 
that can then be transplanted into the recipient, expand 
and exert a desired biological effect (Fig.  1) or direct 
injection of the DNA into the body. GT using ex  vivo 
modified autologous cells could avoid graft rejection and 
GvHD as the transplanted cells and the recipient have 
identical HLA. Therefore, it has long been proposed as 
an alternative treatment to allogeneic HSCT. Different 
gene delivery systems were developed, which provide 
either transient or stable gene transfer. Mechanical meth-
ods such as liposomes or electroporation can introduce 
nucleic acids into cells both in  vitro and in  vivo, albeit 
at low efficacy while damaging many of the cells. Bio-
logical systems, including transposons and viral vectors 
have been used at increasing frequency to insert genetic 
material into cells. Viruses now account for 67% of all 
delivery methods used in GT clinical trials worldwide, 
with adenovirus and retrovirus vectors representing the 
majority. Indeed, as data from the “Gene therapy Clini-
cal Trials Worldwide” update from August 2016 (Fig. 2) 
indicate a steady increase in the use of adeno-associated 
virus and lentivirus vectors in clinical trials [5]. The viral 
vectors differ in the size of the genetic material they can 
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marrow cells
2. Virus altered ex vivo 
so can’t reproduce
3. A gene is 
inserted into 
the virus
4. Altered virus added 
to cells ex vivo
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altered ex vivo
7. Altered cells  transplanted 
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Fig. 1 Ex vivo gene therapy. Patient’s cells are collected from bone marrow, peripheral blood or umbilical cord blood (1). A virus is altered ex vivo to 
increase safety and efficacy of gene delivery (2). A gene is inserted into the altered virus ex vivo (3). The altered virus containing the gene is added 
to the patient’s cells ex vivo (4). The cells are genetically altered ex vivo (5). The patient is treated with chemotherapy or radiotherapy (6). The geneti-
cally altered cells are transplanted into the conditioned patient (7). The genetically altered cells expand in the patient and exert their biological 
effects (8)
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harbor as well as their tropism to tissues and cells. Other 
differences include the virus’ ability to evade the recipi-
ent’s immune system, influencing the potential to trigger 
a neutralizing and possibly harmful immune response. 
Adenovirus associated virus has been commonly used for 
the correction of monogenetic disorders in post-mitotic 
tissues, while retroviral vectors can integrate into the 
host cell genome. Therefore retroviruses are preferred 
for the stable gene transfer into proliferating cells, such 
as hematopoietic stem cells. Indeed, most pre-clinical 
and clinical GT for PID used members of retroviridae 
family, including the Murine leukemia virus (MLV) and 
the human immunodeficiency virus (HIV) of the gamma-
retrovirus and lentivirus (LV) genus, respectively. Insert-
ing the gene of interest ex vivo into cells isolated from the 
patient, which are then given back to the patient, lowers 
the risk of unwanted effects associated with in vivo deliv-
ery, such as ectopic expression of the delivered gene in 
off-target organs. Furthermore, the therapeutic impact 
from ex vivo gene delivery is more robust since the gene-
based correction is not subject to metabolic or renal 
clearance and is less likely to trigger immune responses. 
In some protocols, ex vivo GT may even allow for selec-
tion, expansion and quality control of the modified cells 
before reinfusion, thereby further improving safety and 
efficacy [6]. 
The use of LV vectors raised safety and ethical concerns 
about the possibility of transmitting or promoting HIV 
infection, including generation of replication competent 
LV during vector production or mobilisation of the vec-
tor by endogenous retroviruses in patients’ genomes. 
Some of the strategies developed to mitigate the risk 
for patients and the medical teams include limiting to 
the number of accessory viral genes, splitting the viral 
components to different plasmids, reducing the number 
of viral particles used for transduction and incorporat-
ing self-inactivating (SIN) vectors. Nevertheless, close 
monitoring of patients who receive LV GT is warranted. 
Importantly, despite the increasing use of LV, there have 
not been any reports of accidental development of HIV.
Gene therapy for primary immune deficiencies
GT has been a particularly attractive option for PID. The 
genes responsible for many PID have been identified, the 
diseases have been often fatal at a young age and current 
treatments have commonly been unsatisfactory. Moreo-
ver, the success of HSCT and spontaneous reverse muta-
tions that corrected PID supported the hypothesis that 
autologous GT would be beneficial for such patients. 
Indeed, PID was the first human condition treated with 
GT and continues to be in the forefront of such attempts. 
Ideally, patients should be treated as early as possible 
before suffering significant infections and organ dam-
age, and when the potential for immune reconstitution is 
maximal. Specific indications and inclusion criteria vary 
in accordance to the condition and the protocol. The sub-
sequent discussion will detail the past current and future 
status of PID GT, with emphasis on Canadian experience 
and contributions.
Main text
Gene therapy for adenosine deaminase
Adenosine deaminase (ADA) is a ubiquitous enzyme that 
is crucial for the metabolism of adenosine and 2-deoxy-
adenosine. Impaired function of ADA leads to accumu-
lation of purine metabolites that are particularly toxic to 
the rapidly proliferating bone marrow cells and thymo-
cytes. Inherited ADA defects account for 15–20% of all 
causes of SCID, and some Canadian populations such 
as the Mennonite and Canadian First Nations seem to 
have increased frequency of ADA deficiency [7]. The 
implementation of newborn screening (NBS) for severe 
immune deficiency, and the inclusion of ADA among 
the conditions tested in some of the NBS algorithms, 
such as the one implemented in Ontario, are expected 
to reveal the true incidence of ADA deficiency. T, B and 
Natural Killer (NK) cells dysfunction is often present in 
ADA-deficient patients in infancy. In addition, patients 
may suffer from alveolar proteinosis [8], diverse neuro-
developmental abnormalities [9] as well as bone and car-
tilage malformations [10]. Since the mid-1980, weekly 
injections of polyethylene glycol-modified bovine ADA 
(PEG-ADA) have been used to remove the toxic purine 
metabolites, improve T and B cell functions and correct 
for some of the non-immunologic abnormalities [11]. 
However, PEG-ADA does not cure ADA deficiency, as 
it is effective in only 80% of patients and the immune 



















Fig. 2 Viral vector use in gene therapy trials worldwide 2004–2016. 
Viral vectors account for 67% of the total vectors used for gene 
therapy clinical trials worldwide. The graph depicts the percentage 
(%) of AV adenovirus, RV retrovirus, AAV adeno-associated virus and LV 
lentivirus vector use of the total viral vectors
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recovery often diminishes over time [12]. Moreover, 
the cost of PEG-ADA treatment (>$US 100,000/year) 
restricts its availability for many patients. Nevertheless, 
health Ministries of some Canadian provinces, such as 
Ontario and British Columbia have reluctantly spon-
sored PEG-ADA treatment. HSCT from an unaffected 
HLA identical sibling donor without any chemotherapy 
has been shown to restore immunity in ADA deficient 
patients, and is currently considered the treatment of 
choice [13]. However, HLA identical sibling donors are 
available for only a minority of patients while the use of 
HLA-mismatched related or unrelated donors is associ-
ated with significant morbidity and mortality [14]. These 
disappointing results of HSCT, together with the early 
availability of the ADA gene sequence, prompted the 
investigation of GT for ADA deficiency.
Initial GT trials for ADA deficiency, performed already 
in early 1990, delivered the ADA gene into T lympho-
cytes or umbilical cord blood/bone marrow progenitor 
cells using the murine gamma-retroviral vector. Similar 
to the protocols used for allogeneic HSCT, autologous 
GT were done in ADA-deficient patients without the 
use of cytoreductive conditioning. This was based on the 
assumption that ADA-proficient cells would have a “sur-
vival advantage” over the original ADA-deficient cells. 
Yet, for ethical reasons, patients enrolled in this trial were 
given PEG-ADA, which negated the survival advantage 
of the gene-corrected cells. Hence, despite detection of 
ADA-corrected cells in the host, inadequate amount 
of cells persisted to confer significant clinical benefit. It 
took almost a decade until the group in Italy, led by Drs. 
Aiuti and Naldini reintroduced non-myeloablative doses 
of busulfan or melphalan without PEG-ADA, into the GT 
trials for ADA deficiency [15]. Together with improved 
gene transduction techniques and the use of MLV-
derived replication-deficient vector to deliver the ADA 
cDNA into cells, the Milan group was able to achieve 
lasting ADA expression in cells. This resulted in humoral 
and cellular immune reconstitution, decrease in suscepti-
bility to infections [16] and correction of the bone abnor-
malities [17]. One Canadian patient who participated in 
this study is now almost 10 years after receiving GT and 
is clinically well. Subsequent studies at Great Ormond 
Street in the UK, at The National Human Genome Insti-
tute, the Children’s Hospital Los Angeles, and later the 
UCLA Mattel Children’s Hospital as well as Japan dem-
onstrated the critical role of non-myeloablative pre-
transplantation conditioning in gene therapy for ADA 
SCID [18–20]. Recently, long-term follow-up (range, 2.3–
13.4 years) of the 18 ADA-deficient patients who received 
ADA GT in Milan revealed that all survived [21]. PEG-
ADA was resumed in 3 patients, of which 2 later received 
HSCT from HLA identical sibling donors that were not 
available prior to GT. The relatively short follow-up of 
the ADA-deficient patients who received GT in England 
and North America precludes direct comparison with 
the Milan outcome, yet the overall results and safety of 
all these studies are encouraging. Indeed the success of 
the Milan ADA GT led to commercialization of the viral 
vector by GlaxoSmithKline (GSK) as Strimvelis™, which 
recently received marketing authorization in Europe. The 
impact of such move on ADA GT practicalities, includ-
ing cost for patients and availability in North America are 
still not clear. Impressively, and in contrast to GT trials 
for other PID described below, all ADA-deficient patients 
who received GT in the USA and Europe survived, and 
none experienced abnormal clonal expansions or leuko/
lympho-proliferative disorders. Although analyses of ret-
roviral vector integrations in patients’ cells demonstrated 
insertion near proto-oncogenes sites (including LMO2) 
similar to those found in other PID trials, there was no 
skewing of the T cell repertoire or clonal selection/
expansion in  vivo. Despite the lack of insertional geno-
toxicity with gamma-retroviruses in ADA GT, concerns 
regarding leukemogenesis have led to the development 
of SIN LV vectors. Studies using these vectors for ADA 
deficiency are currently being completed in England 
(ClinicalTrials.gov Identifier: NCT01380990) and the 
USA (ClinicalTrials.gov Identifier: NCT01852071). Dele-
tion of proteins from the vector packaging plasmids and 
the SIN mechanism have made their use safer. Moreover, 
as LV vectors can transduce non-dividing cells, such as 
quiescent hematopoietic stem cells, it is postulated that 
the efficacy of gene delivery into the very early stem cells 
will be improved. Interestingly, based on experiments 
in murine models, the current ADA SIN LV trials con-
tinue the administration of PEG-ADA for 30  days after 
the GT. More than 30 ADA-deficient patients have been 
treated with the SIN LV vector. Immune reconstitution 
has been achieved with no vector-related complications, 
although follow-up period for most patients is still short 
(<3 years). Several ADA-deficient patients from Quebec 
and Ontario, who lacked HLA-matched sibling donors, 
have already received GT under this protocol. Although 
GT is still very expensive (more than $ US 200,000/
patient), the cost is less than the life-long continuation 
of PEG-ADA and possibly even less than an HLA-mis-
matched HSCT that is often associated with prolonged 
admissions and complications. Accordingly, the Ministry 
of Health in several Canadian provinces have approved 
the out-of-county expenses. After the control of infec-
tions and PEG-ADA administration, and coordination by 
the Canadian referring team with the centers perform-
ing the GT, patients typically spend 7–10 days at the GT 
center. During this period, the patients’ bone marrow 
cells are harvested, CD34 expressing cells are selected 
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and transduced with the viral vector, busulfan is admin-
istered, and the gene-corrected cells are infused. Patients 
who are clinically well can return to the referral center 
prior to the development of chemotherapy-induced neu-
tropenia. Close monitoring and frequent follow-ups are 
coordinated between the referring teams and the GT 
centers. In the future, shipping the patients’ bone mar-
row to designated centers might prevent the need for 
them to commute, further simplifying GT and reduc-
ing its costs. Indeed, researchers in the US and UK have 
began investigating the effects of cryopreservation of the 
cells on the success of LV GT for ADA-deficient patients 
(NCT02999984).
Gene therapy for common gamma chain
The interleukin-2 receptor gamma subunit (IL2R) gene 
on the X-chromosome encodes for the gamma chain (γc). 
The chain is a component for intracellular signaling of the 
IL-2, -4, -7, -9, -15, and -21 receptors, thus it is essential to 
the development and function of T, B and NK cells. Inher-
ited defects in the γc are the most common cause of SCID 
in some medical centers [22], although not in others [23]. 
The male patients tend to present during infancy with 
recurrent and opportunistic infections such as Pneumo-
cystis jiroveci pneumonia, unremitting candida and failure 
to thrive. The majority of patients lack T cells, yet expan-
sion of B cells may prevent the characteristic lympho-
penia. In recent years, with the introduction of NBS for 
SCID in most US states, as well as some Canadian prov-
inces and European countries, IL2Rγ-deficient patients 
are being diagnosed earlier, prior to the development of 
infections.
Similar to other forms of SCID, HSCT can cure the 
immune defect caused by the impaired γc signaling. The 
best outcome, with >90% survival and excellent immune 
reconstitution can be achieved with the use of an HLA-
identical sibling donor. Such transplants are typically 
done without any chemotherapy preparation. HSCT 
using HLA matched unrelated donors result in  >80% 
survival and long-term immune reconstitution [4]. In 
recent years, improved outcome has also been reported 
with the use of HLA mismatched family donors, although 
immune reconstitution might be delayed and incom-
plete [24]. Hence, GT has been proposed as an alterna-
tive management option for patients without a suitable 
donor, particularly if patients also have active infections.
Gene therapy trials for X-linked SCID opened in 1999 
and 2001 in Neckar, France and Great Ormond Street, 
UK, respectively. Both sites used autologous CD34+ cells 
that were transduced ex  vivo with a murine gamma-
retroviral vector. Gene-modified cells were returned to 
patients without cytoreductive conditioning. This led to 
improved cellular and humoral immunity, and patients 
were able to combat typical childhood infections and 
resume normal growth and development [25, 26]. How-
ever, 5 of the 20 patients treated at these centers devel-
oped T cell acute lymphoblastic leukemia 2.5–6  years 
after GT. The leukemic transformation was attributed 
to a predilection of the gamma-retroviral vector to inte-
grate near oncogenes. The uncontrolled expression of 
a cytokine receptor important for the proliferation of 
T cells might also have contributed to the malignant 
transformation. While the overall outcome of these ini-
tial studies demonstrated that GT for the γc is possible, 
the significant concerns for safety halted clinical trials 
of GT for this condition (and others) for several years. 
Subsequently, modifications were made to the original 
gamma-retroviral vector to improve its safety, including 
creation of a SIN construct and replacement of the pro-
moter. Results of GT with the modified construct used 
in 9 boys in parallel European and US trials, still without 
preparative conditioning, were recently reported [27]. 
One patient died from a preexisting adenoviral infection 
prior to immune reconstitution, while 7 of the 8 surviv-
ing patients had functional T cells and were free of infec-
tions. Four additional patients have received GT under 
this SIN gamma-retrovirus protocol (ClinicalTrials.gov 
Identifier: NCT01129544), which is close to completion. 
Integration analysis demonstrated no clonal skewing 
and none of the patients have developed malignancy, yet 
the follow-up period is still short. Similar to the trend in 
other PID, GT for X-linked SCID has recently shifted to 
the use SIN LV. A clinical trial using a codon-optimized 
SIN LV vector controlled by the ubiquitous elongation 
factor 1α promoter is being conducted in the US (Clini-
calTrials.gov Identifier: NCT01306019). Interestingly, 
intermediate doses of busulfan were chosen for condi-
tioning patients prior to GT. Initial results of this trial 
have already been published [28]. The 2 older subjects 
(aged 24 and 23  years respectively) cleared pre-existing 
viral infections and were able to stop immunoglobulin 
infusions. One patient died from pulmonary hemorrhage 
27  months after GT while the other patient is clinically 
well 3 years after GT. Three younger patients (7–15 years 
old) were also treated, but conclusions regarding the 
safety and efficacy of this protocol cannot be drawn since 
their follow-up period is less than 1 year. In 2017, Boston 
Children’s and several collaborators are expected to open 
another trial with a SIN LV vector that will also involve 
administration of low dose busulfan in order to gener-
ate IL2Rγ-expressing B cells and to correct the humoral 
immunity. Future studies comparing the survival, compli-
cations and long-term immune reconstitution following 
HSCT from different donors and GT, with and without 
conditioning, will enable better assessment of the various 
treatment options for patients with X-linked SCID.
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Using targeted genome editing by artificial nucleases is 
another interesting approach, although it is still in pre-
clinical stages. These include the zinc finger nucleases 
(ZFNs), the transcription activator-like effector nucle-
ases (TALENs) and the RNA-guided clustered regularly 
interspaced short palindromic repeats (CRISPR/Cas) 
nucleases that can efficiently and specifically cause a 
DNA break at a preselected site. Using ZFN and tailor-
ing of delivery platforms and culture conditions, Nal-
dini’s group were able to target a corrective cDNA into 
the IL2Rγ gene of stem cells from a patient with X-linked 
SCID, which led to normalization of hematopoiesis and 
generation of functional lymphoid cells [29].
Gene therapy for Wiskott Aldrich Syndrome
The WAS gene on the X chromosome encodes for the 
cytoplasmic WAS protein that affects actin polymeriza-
tion in hematopoietic cells. WAS protein is important for 
leukocyte migration and formation of the immunologic 
synapse. WAS is characterized by increased susceptibil-
ity to infections, eczema, as well as the bleeding caused 
by the thrombocytopenia with platelets of low size and 
impaired function [30]. Patients also suffer from diverse 
autoimmune manifestations that may further contrib-
ute to the development of thrombocytopenia, vascu-
lar abnormalities and malignancies. Antibiotics and 
immunoglobulin prophylaxis as well as platelet transfu-
sions and immune suppression may provide temporary 
relief for affected patients, yet most patients eventually 
develop life-threatening complications. Despite support-
ive care, the median life expectancy of patients is mark-
edly reduced. Predicting outcome for specific patients 
based on the mutation, protein expression or clinical 
grading have been challenging, hence in most cases there 
should be an attempt to cure the disease. HSCT for WAS 
have been performed for almost 50  years, with excel-
lent results, particularly if done early in life, with a well 
matched donor [31]. Indeed, the London group reported 
100% survival rate in 34 patients treated between 1996 
and 2016 using a variety of graft sources and tailored pre-
parative regimens [32]. Nevertheless, GT is an attractive 
option for patients already harboring infections such as 
CMV, suffering from significant co-morbidities or lacking 
suitable HSCT donors.
The first WAS GT trial was performed between 
2006 and 2009 in Munich, Germany and included 10 
patients with severe phenotype. Patients received low 
doses of busulfan followed by transfusions of autolo-
gous CD34+  cells transduced with a WASP-expressing 
gamma-retroviral vector. GT reconstituted T cell function 
and antibody production. Platelets size normalized and 
their numbers increased, albeit often remaining below 
normal range, with resolution of hemorrhagic diatheses 
[33]. Yet, between 14 months and 5 years after gene ther-
apy, 7 patients developed acute leukemia. Similar to the 
findings in X-linked SCID GT, the increased tendency of 
retroviruses to integrate near oncogenes, such as LMO2, 
was the probable reason. Subsequently, there have been 
3 GT trials in Italy, the USA as well as France and Eng-
land using a SIN LV and the endogenous WAS promoter 
[34–36]. As of April 2016, 8 patients received GT for 
WAS following reduced intensity conditioning in Milan, 
Italy (ClinicalTrials.gov Identifier: NCT01515462). At 
a median follow-up length of 3.8  years (range: 0.6–5.9), 
they are all alive and well. After immune reconstitution, 
marked reduction in severe infection rate was observed 
and 5 patients were able to stop immunoglobulin supple-
mentation. There was a noticeable decrease in moderate-
severe bleeding frequency and all patients became platelet 
transfusion independent, although platelet numbers 
have remained below normal. Importantly, no abnormal 
clonal proliferations were observed [37]. Seven patients 
suffering from WAS received GT in France (ClinicalTri-
als.gov Identifier: NCT01347346) and England (Clini-
calTrials.gov Identifier: NCT01347242). At the time of 
the last reported follow-up, 6 were alive with no severe 
bleeding episodes, and were free of infections and leuke-
mic events. One patient died 7  months after GT due to 
preexisting, refractory herpes virus infections. GT was 
also beneficial in a 30 year old patient with severe WAS 
manifesting with multiple inflammatory complications 
and lympho-proliferation who required long-term immu-
nosuppressive treatment for disease control [38]. Another 
LV GT trial for WAS at Boston, USA (ClinicalTrials.gov 
Identifier: NCT01410825) has enrolled two patients who 
are reported to have improved immune and hematologic 
parameters without genotoxicity at early time points. 
The trials in France, UK and USA are currently recruiting 
patients. It is expected that the results from these autolo-
gous GT studies will enable better comparison with those 
of allogenic HSCT, including susceptibility to autoim-
munity that has been frequently reported following par-
tial correction of WAS [39].
Gene therapy for JAK3 deficiency
The JAK3 protein kinase delivers signalling into the cells 
following stimulation of the γc. Apart from the inherit-
ance, which is autosomal recessive in JAK3 deficiency, 
patient often display a SCID phenotype similar to that 
seen in γc deficient patients. A single JAK3-deficient 
patient who failed HSCT received retroviral GT, however 
the results were only published in abstract form. Disap-
pointingly, there was no evidence of immune reconsti-
tution at 7 months posttreatment [40]. This clinical trial 
was stopped following the occurrence of leukemia in 
X-linked SCID GT.
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Gene therapy for chronic granulomatous disease
CGD is caused by impaired function of the NADPH oxi-
dase complex that is important for the production of 
reactive oxygen species in phagocytes. Consequently, 
patients are susceptible to infections by catalase-positive 
microorganisms such as Staphylococcus aureus, Nocar-
dia spp, Serratia marcescens, Burkholderia cepacea and 
Salmonella spp as well as Aspergillus species. Infected 
areas typically include the lung, lymph nodes, liver, bones 
and skin. Dysregulated immune responses often result in 
granuloma formation and other inflammatory disorders 
involving the bowel. The most common form of CGD 
is caused by defects in the in the X-linked CYBB gene, 
which encodes gp91phox. Recognizing the poor long-
term prognosis of patients with CGD, particularly those 
with markedly reduced neutrophil oxidative burst [41] 
and improvement in transplantation techniques have 
led to increasing numbers of patients who have bene-
fited from HSCT [42]. Nevertheless, since patients often 
experience graft rejection or develop GvH disease and 
inflammatory exacerbations, GT for the X-linked CYBB 
gene defects has been explored. The first GT trial for 
CGD used a gamma-retroviral vectors to deliver human 
gp91phox. However, only few gene-corrected cells per-
sisted, possibly because no pre-GT conditioning was 
given. Three patients who received GT at National Insti-
tute of Health (NIH) following reduced intensity condi-
tioning showed slightly better engraftment and some 
clinical improvement; However 1 patient died 6 months 
after GT from a fungal infection [43]. GT performed in 
Germany involving 2 patients with CGD, using a similar 
vector, albeit with a different transcriptional control, led 
to the correction of 15% of the neutrophils shortly after 
treatment. Unfortunately, both patients developed fatal 
myelodysplasia secondary to insertional mutagenesis 
[44]. Similar complications were also noted in 2 addi-
tional children with CGD treated in Switzerland, and the 
patients were rescued with HSCT. Patients with CGD 
also received unsuccessful GT in London (4 patients) and 
Seoul (2 patients). To improve efficacy and safety of GT 
for CGD, SIN gamma-retroviral vector and a LV vector 
expressing gp91phox were developed with preparative 
conditioning regimens that are effective and well toler-
ated. Moreover, the newer constructs carry myeloid-
specific promoters and/or allow for post-transcriptional 
down-regulation of expression in hematopoietic stem 
cells. Currently 3 US sites (NIH, Boston and Los Ange-
les) are recruiting patients with CGD who are 23 months 
or older for a trial with a 3rd generation SIN LV, which 
directs gp91phox expression from a codon-optimized 
form of the CYBB gene preferentially to myeloid cells 
(ClinicalTrials.gov Identifier: NCT02234934). Simi-
lar studies using LV are being conducted in Frankfurt, 
London and Zurich (ClinicalTrials.gov Identifier: 
NCT01855685), while the site in Paris is also accept-
ing younger children (ClinicalTrials.gov Identifier: 
NCT02757911). So far, a single child with CGD and inva-
sive liver, brain, abdominal, and pulmonary infections, 
and inflammatory complications received GT in Europe. 
He was reported to be stable for 3 months post GT, but 
then developed fatal respiratory complications [45].
Gene therapy for leukocyte adhesion defect
LAD is characterized by delayed separation of the cord, 
neutrophilia, severe gingivitis and periodontitis, and 
recurrent, cutaneous, non-healing wounds lacking puss 
formation. Patients commonly suffer from severe recur-
rent systemic bacterial infections. The classical form of 
LAD is caused by defects in the CD18 gene, also known 
as the beta-2 subunit of the leukocyte integrin family or 
ITGB2. Allogeneic HSCT are the only definitive cure for 
LAD, but complete donor engraftment has been difficult 
to achieve [46]. Two patients with severe LAD received 
RV mediated CD18 gene-corrected stem cells. After the 
infusion, only 0.1% of the patients’ neutrophils expressed 
CD18, and these cells disappeared within 2  months of 
GT. Subsequent GT for LAD has been restricted to ani-
mal models [47].
Gene therapy for other PID
GT for other PID are currently at various in  vitro and 
in  vivo pre-clinical stages (Table  1), often needing to 
address unique challenges associated with specific 
diseases.
The future of gene therapy
In recent years, advances in gene manipulation and 
vector design are expected to bring GT closer to clini-
cal reality. A major breakthrough is the development of 
site-specific gene editing tools. By creating site-specific 
breaks in the DNA near the location of a known muta-
tion, a cell’s natural repair mechanisms can be utilized 
to incorporate normal segments of DNA. This strategy 
positions genes in their endogenous locations under the 
control of normal regulatory elements, thereby decreas-
ing the risk of insertional mutagenesis or ectopic protein 
expression. GT for PID uses HSC derived from patients’ 
bone marrow, mobilized peripheral mononuclear cells, or 
rarely from the recipient’s own cord blood. In the upcom-
ing years, advances in reprograming blood, skin and 
other tissues into pluri-potent stem cells (iPSC) followed 
by ex  vivo differentiation of these cells into hematopoi-
etic and immune lineages are expected to limit the need 
for invasive procedures. Another important development 
is the ability to efficiently freeze, thaw and expand stem 
cells. This may circumvent the need to send Canadian 
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patients, and families, out of the country to the few loca-
tions where gene delivery is currently being performed. 
Centralizing stem cells manipulation and gene delivery 
will enable resources and expertise to concentrate at spe-
cific GMP facilities, while allowing patients to continue 
receiving care at local Canadian centers experienced in 
transplantations. Centralization will also facilitate moni-
toring for long-term complications secondary to GT and 
conduction of novel GT trials.
Conclusions
The use of GT to cure PID is developing rapidly. While 
there are still significant challenges, the recently 
improved safety and efficacy measures in GT suggest that 
such treatment may soon become a standard of care for 
diverse PID, including many affected Canadian patients.
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